CY1114155T1 - Πολυμερικες κατασκευες - Google Patents

Πολυμερικες κατασκευες

Info

Publication number
CY1114155T1
CY1114155T1 CY20131100605T CY131100605T CY1114155T1 CY 1114155 T1 CY1114155 T1 CY 1114155T1 CY 20131100605 T CY20131100605 T CY 20131100605T CY 131100605 T CY131100605 T CY 131100605T CY 1114155 T1 CY1114155 T1 CY 1114155T1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
domain
multilateral
constructions
polymerization
Prior art date
Application number
CY20131100605T
Other languages
English (en)
Inventor
Abraham Scaria
Peter Pechan
Samuel Wadsworth
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1114155T1 publication Critical patent/CY1114155T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)

Abstract

Πολυμερικές πρωτεΐνες σύντηξης μιας περιοχής όμοιας με την Ιg της F1t-1 καθίστανται λειτουργικές με την προσθήκη ή σύνδεση μιας ρίζας. Ξενιστές που κωδικοποιούν τις πρωτεΐνες σύντηξης και κύτταρα του υποδοχέα που εκφράζουν τις πρωτεΐνες σύντηξης μπορούν να χρησιμοποιηθούν θεραπευτικά ώστε να εμποδίσουν την νεοαγγείωση σε άτομα με παθολογικές καταστάσεις που σχετίζονται με την νεοαγγείωση. Τέτοιες καταστάσεις περιλαμβάνουν ηλικιακή εκφύλιση της ώχρας κηλίδας, καρκίνο, ψωρίαση, πολλαπλασιαστική διαβητική αμφιβληστροειδοπάθεια, άσθμα, ραγοειδίτιδα, οστεοαρθρίτιδα και ρευματοειδή αρθρίτιδα. Τα ίδια μέσα πολυμερισμού που χρησιμοποιούνται για μια περιοχή όμοια με την Ιg της FΙt-1, δηλαδή ένας συνδετήρας και μια επικράτεια πολυμερισμού, μπορούν να χρησιμοποιηθούν για άλλα πολυπεπτίδια συμπεριλαμβανομένων εξωκυτταρικών υποδοχέων, μεταβλητών περιοχών αντισωμάτων, κυτοκινών, χημοκινών και παραγόντων ανάπτυξης.
CY20131100605T 2004-09-13 2013-07-17 Πολυμερικες κατασκευες CY1114155T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60888704P 2004-09-13 2004-09-13
US65820905P 2005-03-04 2005-03-04
EP10165159.4A EP2229956B1 (en) 2004-09-13 2005-09-13 Multimeric constructs

Publications (1)

Publication Number Publication Date
CY1114155T1 true CY1114155T1 (el) 2016-08-31

Family

ID=36060586

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100605T CY1114155T1 (el) 2004-09-13 2013-07-17 Πολυμερικες κατασκευες

Country Status (16)

Country Link
US (4) US7928072B2 (el)
EP (2) EP2229956B1 (el)
JP (1) JP4944032B2 (el)
CN (1) CN101094688B (el)
AT (1) ATE470454T1 (el)
BR (1) BRPI0515264B1 (el)
CY (1) CY1114155T1 (el)
DE (1) DE602005021811D1 (el)
DK (2) DK2229956T3 (el)
ES (2) ES2347340T3 (el)
HK (1) HK1144663A1 (el)
IL (2) IL181839A0 (el)
MX (1) MX2007002942A (el)
PL (2) PL1804835T3 (el)
PT (2) PT1804835E (el)
WO (1) WO2006031689A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1804835E (pt) * 2004-09-13 2010-10-04 Genzyme Corp Construções multiméricas
EP2203476B1 (en) * 2007-09-25 2016-10-26 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
WO2009105669A2 (en) * 2008-02-20 2009-08-27 Genzyme Corporation Angiogenesis inhibition
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
DK3357511T3 (da) 2011-06-30 2020-08-03 Genzyme Corp Inhibitorer af t-celleaktivering
DK2744508T3 (en) * 2011-08-19 2018-02-19 Harvard College VEGF BINING PROTEIN TO BLOCK ANGIOGENESES
CN102399292A (zh) * 2011-09-14 2012-04-04 盛剑鹏 重组干细胞因子与免疫球融合蛋白及其制备
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
WO2013163419A1 (en) * 2012-04-25 2013-10-31 Ligacept Llc Broad spectrum erbb ligand binding molecules and methods for their use
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CN104411718B (zh) * 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN106163573A (zh) * 2014-02-06 2016-11-23 建新公司 用于治疗和预防黄斑变性的组合物及方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
CN114805598A (zh) * 2019-04-28 2022-07-29 广州市雷德生物科技有限公司 促进蛋白二聚体形成的拉链扣结构及其应用
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116370399A (zh) * 2021-12-31 2023-07-04 康码（上海）生物科技有限公司 用于病毒的防护和/或治疗的膜剂及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH03233530A (ja) 1990-02-09 1991-10-17 Fuji Photo Optical Co Ltd カメラ
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
JPH10507061A (ja) 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
DE69628744D1 (de) 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
AU1695197A (en) 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
WO1998013071A1 (en) 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP1173191A4 (en) 1997-05-13 2004-12-01 Univ California NOVEL ANTI-ANGIOGENIC PEPTIDE AGENTS, USE OF THE SAME FOR THERAPY AND DIAGNOSIS
US5952916A (en) 1998-05-28 1999-09-14 Atras Auto Co., Ltd Hammer-equipped emergency signal device
DE69832798T2 (de) 1997-06-03 2006-09-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
US5963622A (en) 1997-07-29 1999-10-05 3Com Corporation Mode signalling method and apparatus
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP1183051A2 (en) 1999-03-15 2002-03-06 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2002024234A2 (en) 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1349574A2 (en) 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US6886200B2 (en) * 2001-01-25 2005-05-03 Hill-Rom Services, Inc. Hydraulic actuator apparatus for a surgical table
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
US7078411B2 (en) * 2001-05-16 2006-07-18 Umdnj (Univ Of Medicine & Dentist. Of Nj) Phospholipid transfer protein (PLTP) and cholestoral metabolism
EP1490113A4 (en) 2002-03-20 2007-05-02 Univ Florida ADENO-ASSOCIATED RECOMBINANT VIRAL VECTOR (RAAV) COMPOSITIONS AND CORRESPONDING METHODS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
WO2004085479A2 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
PT1804835E (pt) * 2004-09-13 2010-10-04 Genzyme Corp Construções multiméricas
MX2007007165A (es) 2004-12-17 2007-08-14 Genentech Inc Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior.
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers

Also Published As

Publication number Publication date
EP1804835B9 (en) 2010-09-29
PL2229956T3 (pl) 2013-09-30
EP2229956A1 (en) 2010-09-22
US8658602B2 (en) 2014-02-25
ES2407859T3 (es) 2013-06-14
IL216095A (en) 2013-10-31
ATE470454T1 (de) 2010-06-15
EP1804835B1 (en) 2010-06-09
CN101094688B (zh) 2013-05-01
ES2347340T3 (es) 2010-10-28
EP2229956B1 (en) 2013-04-24
EP1804835A4 (en) 2008-07-30
JP2008512127A (ja) 2008-04-24
PL1804835T3 (pl) 2010-11-30
US20180155417A1 (en) 2018-06-07
CN101094688A (zh) 2007-12-26
DK1804835T3 (da) 2010-10-11
BRPI0515264A (pt) 2008-07-15
BRPI0515264B1 (pt) 2018-12-18
MX2007002942A (es) 2008-03-05
JP4944032B2 (ja) 2012-05-30
PT1804835E (pt) 2010-10-04
US7928072B2 (en) 2011-04-19
WO2006031689A2 (en) 2006-03-23
US9815892B2 (en) 2017-11-14
US20110268735A1 (en) 2011-11-03
US20070224178A1 (en) 2007-09-27
EP1804835A2 (en) 2007-07-11
PT2229956E (pt) 2013-07-31
IL181839A0 (en) 2007-07-04
WO2006031689A3 (en) 2006-07-06
DE602005021811D1 (de) 2010-07-22
IL216095A0 (en) 2011-12-29
HK1144663A1 (en) 2011-03-04
US20140193411A1 (en) 2014-07-10
DK2229956T3 (da) 2013-07-29

Similar Documents

Publication Publication Date Title
CY1114155T1 (el) Πολυμερικες κατασκευες
MX2020006408A (es) Moléculas de unión al antígeno biespecíficas.
CY1117241T1 (el) Αντισωματα anti-igf
MX2021004660A (es) Moleculas de union multivalentes a base de igm- e iga-fc.
CY1121558T1 (el) Διλειτουργικα πολυπεπτιδια
CY1124091T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
EP4342912A3 (en) Binding molecules that modulate a biological activity expressed by a cell
CY1119755T1 (el) Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms
CY1112456T1 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
CY1116037T1 (el) Αντισωματα κατα της ακτιβινης α και χρησεις αυτων
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
CY1112840T1 (el) Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινης
IN2015DN01361A (el)
NZ602161A (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CY1124849T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
IS7677A (is) Mótlyf Nogo-viðtaka
EA202190542A1 (ru) Сконструированные биспецифические белки
WO2016179518A8 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
WO2012040323A3 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
ATE544854T1 (de) Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür
IS8339A (is) Mótlyf viðtaka NOGO
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
CY1115960T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer